Citation map · Study

Fixed dose drug combinations – are they pharmacoeconomically sound? Findings and implications especially for lower- and middle-income countries

13 references·2 citing·44 second hop

this work references cited by second hop

References

2008Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis926 cited
2016Essential medicines for universal health coverage661 cited
2017Monitoring universal health coverage within the Sustainable Development Goals: development and baseline data for an index of essential health services447 cited
2017Sustainable Development Goals (SDGs), and their implementation371 cited
2018Out-of-Pocket Payments, Catastrophic Health Expenditure and Poverty Among Households in Nigeria 2010292 cited
2006Cardiovascular disease prevention with a multidrug regimen in the developing world: a cost-effectiveness analysis273 cited
2016Prices, Costs, and Affordability of New Medicines for Hepatitis C in 30 Countries: An Economic Analysis255 cited
2008Fixed dose drug combinations (FDCs): rational or irrational: a view point159 cited
2018Barriers for Access to New Medicines: Searching for the Balance Between Rising Costs and Limited Budgets159 cited
2014Multiple policies to enhance prescribing efficiency for established medicines in Europe with a particular focus on demand-side measures: findings and future implications129 cited
2014Are new models needed to optimize the utilization of new medicines to sustain healthcare systems?123 cited
2011Policies to Enhance Prescribing Efficiency in Europe: Findings and Future Implications113 cited
2018Systemic Measures and Legislative and Organizational Frameworks Aimed at Preventing or Mitigating Drug Shortages in 28 European and Western Asian Countries

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work

References

Cited by